Antisense Anticancer Oligonucleotide Therapeutics

Authors: Wang H.; Prasad G.; Buolamwini J.K.; Zhang R.

Source: Current Cancer Drug Targets, Volume 1, Number 3, November 2001 , pp. 177-196(20)

Publisher: Bentham Science Publishers

Abstract:

Recent progress made in molecular biology, biotechnology, and genetics, especially in identifying, cloning, sequencing and characterization of normal and pathogenic genes, has led to the development of genetic therapy. Major efforts in the field can be summarized in two general approaches: gene therapy and antisense therapy. The second is to deliver to the target cells antisense molecules that target to mRNA with which they can hybridize and specifically inhibit the expression of pathogenic genes. Antisense oligonucleotides offer the possibility of specific, rational, genetic-based therapeutics. With encouraging results from preclinical and clinical studies of antisense oligonucleotides in the past decade, significant progress has been made in developing antisense therapy, with the first antisense drug now being approved for clinical use. In this article, we will discuss approaches to developing these drugs from preclinical to clinical settings. Of particular interest for the area of human cancer therapy, several cancer targets, including bcl-2, BCR-ABL, C-raf-1, Ha-ras, c-myc, PKC, PKA, p53 and MDM2, are reviewed as examples to illustrate the progress in this field and emphasize the importance of target selection and advanced antisense chemistry in the development of antisense therapy.

Keywords: Antisense Anticancer Oligonucleotide; Bc1-2; Bcr-abl; Antisense oligondeoxyucleotides; Mixed backbone oligonucleotides mbo; Anticancer agents; C myc; Ras; C-raf-1; Camp dependent protein kinase pka

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1568009013334133

Publication date: 2001-11-01

• Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
  Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
  As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

• In this: publication
• By this: publisher
• In this Subject: Oncology ,  Pharmacology
• By this author: Wang H. ;  Prasad G. ;  Buolamwini J.K. ;  Zhang R.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers